History of bariatric surgery and COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study

Archive ouverte

Blanchard, Claire | Perennec, T. | Smati, Sarra | Tramunt, B. | Guyomarch, B. | Bigot-Corbel, E. | Bordier, L. | Borot, S. | Bourron, O. | Caussy, C. | Coffin-Boutreux, C. | Dutour, A. | Germain, N. | Gonfroy-Leymarie, C. | Meyer, L. | Prevost, G. | Roussel, R. | Seret-Begue, D. | Thivolet, C. | Vergès, B. | Pichelin, M. | Gourdy, P. | Hadjadj, S. | Wargny, M. | Pattou, F. | Cariou, B.

Edité par CCSD ; Wiley -

International audience. OBJECTIVE: This study assessed the impact of a history of metabolic and bariatric surgery (MBS) on the clinical outcomes in patients with type 2 diabetes (T2D) and severe obesity hospitalized for COVID-19. METHODS: In this post hoc analysis from the nationwide observational CORONADO (Coronavirus SARS-CoV2 and Diabetes Outcomes) study, patients with T2D and a history of MBS were matched with patients without MBS for age, sex, and BMI either at the time of MBS or on admission for COVID-19. The composite primary outcome (CPO) combined invasive mechanical ventilation and/or death within 7 and 28 days following admission. RESULTS: Out of 2,398 CORONADO participants, 20 had a history of MBS. When matching for BMI at the time of MBS and after adjustment for diabetes duration, the CPO occurred less frequently within 7 days (3 vs. 17 events, OR: 0.15 [0.01 to 0.94], p = 0.03) and 28 days (3 vs. 19 events, OR: 0.11 [0.01 to 0.71], p = 0.02) in patients with MBS (n = 16) vs. controls (n = 44). There was no difference in CPO rate between patients with MBS and controls when matching for BMI on admission. CONCLUSIONS: These data are reassuring regarding COVID-19 prognosis in patients with diabetes and a history of MBS compared with those without MBS.

Suggestions

Du même auteur

Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19

Archive ouverte | Lalau, Jean-Daniel | CCSD

International audience. AIMS: Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for COVID-19....

Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalized for COVID-19. La metformine est associée à une moindre mortalité chez les patients diabétiques hospitalisés pour la COVID-19

Archive ouverte | Lalau, Jean-Daniel | CCSD

International audience. Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on the prognosis of patients with type 2 diabetes hospitalised for COVID-19. W...

Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients

Archive ouverte | Blanchard, C. | CCSD

International audience. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a master regulator of low-density lipoprotein cholesterol (LDL-C) metabolism, acting as an endogenous inhibitor of the LDL receptor. W...

Chargement des enrichissements...